Short answer
CODEXIS, INC. (CDXS) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $15M (up 102.1% year over year) with net income of −$9M.
Q1 2026 key financials · XBRL
- Revenue
- $15M
- +102.1% YoY
- Net income
- −$9M
- +57.9% YoY
- Operating margin
- -52.7%
- EPS (diluted)
- −$0.10
- +60.0% YoY
Source: XBRL data from the CODEXIS, INC. (CDXS) Q1 2026 10-Q on SEC EDGAR. USD.
CODEXIS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $15.248M, up 102% YoY from $7.543M
- Research and development revenue $8.057M, up 443% YoY from $1.484M
- Product gross margin 71% vs 55% YoY, driven by higher-profit product mix
- Cash and equivalents $36.571M vs $50.793M at December 31, 2025
- Operating cash outflow $13.150M vs $13.798M YoY; management expects funding for at least 12 months
Risk Factors
- BIOSECURE Act enacted December 2025, potentially restricting foreign CMO relationships and U.S. federal contracting
- FDA classification risk heightened by planned GMP-grade siRNA collaborations and possible enforcement against noncompliant products
- Customer concentration: customers contributing at least 10% represented 64% of revenue in Q1 2026
- Third-party manufacturing dependence: substantially all enzymes produced at Redwood City, Lactosan, and ACSD
- Net loss $8.7 million and accumulated deficit $615.5 million as of March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CODEXIS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.